Active substance Ciclosporin
Domain Neurological disorders
Reason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)
Main indication Eye disorders
Extended indication Treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.


Proprietary name Verkazia
Manufacturer Santen
Mechanism of action Immunosuppression
Route of administration Ocular
Therapeutical formulation Eye drops
Budgetting framework Extramural (GVS)


Registration route Centralised (EMA)
Type of trajectory Accelerated assessment
Submission date December 2016
Expected Registration July 2018
Orphan drug Yes
Registration phase Registered
Additional comments Positieve CHMP opinie 21 juli 2017. Registratie in juli 2018.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 870

Market share is generally not included unless otherwise stated.

References EMA
Additional comments Vernal keratoconjunctivitis affected between 1 to 3 in 10,000 people in Europe.' (EMA). Dit zijn 5.100 patiënten per 17 miljoen Nederlanders. Gezien de behandeling alleen van 4-18 jaar gegeven zal worden, en dit 17% van de Nederlandse bevolking betreft, komen er waarschijnlijk maximaal 870 patiënten in aanmerking voor deze behandeling.

Expected cost per patient per year

Additional comments Flacon ciclosporin 10 ml, 1mg/ml: €37,04.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.